<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03520712</url>
  </required_header>
  <id_info>
    <org_study_id>BMN 270-203</org_study_id>
    <secondary_id>2017-000662-29</secondary_id>
    <nct_id>NCT03520712</nct_id>
  </id_info>
  <brief_title>Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5</brief_title>
  <acronym>270-203</acronym>
  <official_title>A Phase 1/2 Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients With Residual FVIII Levels ≤ 1 IU/dL and Pre-existing Antibodies Against AAV5</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMarin Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted by BioMarin Pharmaceutical Inc. as an open label, single dose&#xD;
      study to determine the safety of valoctocogene roxaparvovec (an Adenovirus-Associated Virus&#xD;
      (AAV) based gene therapy vector) in severe Hemophilia A patients with pre-existing antibodies&#xD;
      against AAV5.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 3, 2018</start_date>
  <completion_date type="Anticipated">November 2026</completion_date>
  <primary_completion_date type="Anticipated">November 2026</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of a single intravenous administration of BMN 270 in severe HA subjects with pre-existing antibody to AAV5 vector capsid, including development of FVIII neutralizing antibody.</measure>
    <time_frame>61 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of BMN 270 defined as FVIII activity at or above 5 IU/dL at Week 26.</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of BMN 270 on usage of exogenous FVIII replacement therapy.</measure>
    <time_frame>61 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of BMN 270 on the number of bleeding episodes requiring exogenous FVIII therapy.</measure>
    <time_frame>61 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hemophilia A</condition>
  <condition>Gene Therapy</condition>
  <condition>Clotting Disorders</condition>
  <condition>Blood Disorder</condition>
  <arm_group>
    <arm_group_label>valoctocogene roxaparvovec Open Label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of BMN270 at a dose of 6E13 vg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Valoctocogene Roxaparvovec</intervention_name>
    <description>Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A</description>
    <arm_group_label>valoctocogene roxaparvovec Open Label</arm_group_label>
    <other_name>BMN 270</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males ≥ 18 years of age with hemophilia A and residual FVIII levels ≤ 1 IU/dL as&#xD;
             evidenced by medical history, at the time of signing the informed consent.&#xD;
&#xD;
          2. Detectable pre-existing antibodies against the AAV5 vector capsid as measured by AAV5&#xD;
             total antibody ELISA.&#xD;
&#xD;
          3. Subject must have been on prophylactic FVIII replacement therapy for at least 12&#xD;
             months prior to study entry.&#xD;
&#xD;
          4. No previous documented history of a detectable FVIII inhibitor, and results from a&#xD;
             Bethesda assay or Bethesda assay with Nijmegen modification of less than 0.6 Bethesda&#xD;
             Units (BU) (or less than 1.0 BU for laboratories with a historical lower sensitivity&#xD;
             cutoff for inhibitor detection of 1.0 BU) on 2 consecutive occasions at least one week&#xD;
             apart within the past 12 months (at least one of which should be tested at the central&#xD;
             laboratory).&#xD;
&#xD;
          5. Sexually active participants must agree to use an acceptable method of effective&#xD;
             contraception. Participants must agree to contraception use for at least 12 weeks&#xD;
             post-infusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any evidence of active infection including COVID-19, or any immunosuppressive&#xD;
             disorder, including HIV infection.&#xD;
&#xD;
          2. Evidence of liver dysfunction as assessed by liver tests and most recent, prior&#xD;
             FibroScan or liver biopsy showing significant fibrosis of 3 or 4 as rated on a scale&#xD;
             of 0-4 on the Batts-Ludwig (Batts 1995) or METAVIR (Bedossa 1996) scoring systems, or&#xD;
             an equivalent grade of fibrosis if an alternative scale is used.&#xD;
&#xD;
          3. Chronic or active hepatitis B or C as evidenced by testing at screening.&#xD;
&#xD;
          4. Active malignancy, except non-melanoma skin cancer, or history of hepatic malignancy.&#xD;
&#xD;
          5. Any condition that, in the opinion of the investigator or Sponsor would prevent the&#xD;
             patient from fully complying with the requirements of the study (including&#xD;
             corticosteroid treatment and/or use of alternative immunosuppressive agents outlined&#xD;
             in the protocol) and/or would impact or interfere with evaluation and interpretation&#xD;
             of subject safety or efficacy result.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Biological males only.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>BioMarin Pharmaceutical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nantes University Hospital Center - Hotel Dieu Hospital</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Maxeke Johannesburg Academic Hospital, Hemophilia Comprehensive Care Center</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 10, 2018</study_first_submitted>
  <study_first_submitted_qc>April 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2018</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemophilia A</keyword>
  <keyword>Blood Coagulation Disorders, Inherited</keyword>
  <keyword>Blood Coagulation Disorders</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Coagulation Protein Disorders</keyword>
  <keyword>Hemorrhagic Disorders</keyword>
  <keyword>Genetic Diseases, Inborn</keyword>
  <keyword>Factor VIII</keyword>
  <keyword>Coagulants</keyword>
  <keyword>AAV5 antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

